JP2025501028A5 - - Google Patents
Info
- Publication number
- JP2025501028A5 JP2025501028A5 JP2024538272A JP2024538272A JP2025501028A5 JP 2025501028 A5 JP2025501028 A5 JP 2025501028A5 JP 2024538272 A JP2024538272 A JP 2024538272A JP 2024538272 A JP2024538272 A JP 2024538272A JP 2025501028 A5 JP2025501028 A5 JP 2025501028A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- sequence
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293242P | 2021-12-23 | 2021-12-23 | |
| US63/293,242 | 2021-12-23 | ||
| PCT/US2022/082214 WO2023122714A2 (en) | 2021-12-23 | 2022-12-22 | Compositions and methods for treatment of thyroid eye disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501028A JP2025501028A (ja) | 2025-01-16 |
| JP2025501028A5 true JP2025501028A5 (enExample) | 2026-01-05 |
Family
ID=86903795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538272A Pending JP2025501028A (ja) | 2021-12-23 | 2022-12-22 | 甲状腺眼疾患を治療するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240352133A1 (enExample) |
| EP (1) | EP4453036A4 (enExample) |
| JP (1) | JP2025501028A (enExample) |
| KR (1) | KR20240117639A (enExample) |
| CN (1) | CN118742567A (enExample) |
| AU (1) | AU2022420605A1 (enExample) |
| CA (1) | CA3240723A1 (enExample) |
| MX (1) | MX2024007968A (enExample) |
| WO (1) | WO2023122714A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3195512A1 (en) | 2020-10-14 | 2022-04-21 | Vahe Bedian | Compositions and methods for treatment of thyroid eye disease |
| JP2024531151A (ja) | 2021-08-10 | 2024-08-29 | ビリジアン セラピューティクス， インコーポレイテッド | 甲状腺眼疾患の処置のための組成物、用量および方法 |
| TW202421661A (zh) * | 2022-06-10 | 2024-06-01 | 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 | Igf1r抗體 |
| CN122003247A (zh) | 2023-07-07 | 2026-05-08 | 维里迪安治疗公司 | 治疗活动性和慢性甲状腺眼病的方法 |
| CN122122186A (zh) * | 2023-09-06 | 2026-05-29 | 维里迪安治疗公司 | 抗igf-1r抗体的药物组合物 |
| US20250197511A1 (en) * | 2023-12-13 | 2025-06-19 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| AU2024408268A1 (en) * | 2023-12-17 | 2026-07-09 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
| TW202615481A (zh) * | 2024-09-09 | 2026-04-16 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之方法 |
| WO2026095974A1 (en) | 2024-10-30 | 2026-05-07 | Horizon Therapeutics Ireland Dac | Methods of treating thyroid eye disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| EP2863947B1 (en) * | 2012-06-21 | 2018-03-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
| TW201920285A (zh) * | 2013-04-29 | 2019-06-01 | 瑞士商赫孚孟拉羅股份公司 | 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途 |
| EA035517B1 (ru) * | 2014-03-06 | 2020-06-29 | Нэшнл Рисеч Каунсил Оф Канада | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения |
| US20230235011A1 (en) * | 2020-05-25 | 2023-07-27 | Beijing Beyond Biotechnology Co., Ltd | Fc-cd80 fusion protein and conjugates thereof and their uses |
-
2022
- 2022-12-22 MX MX2024007968A patent/MX2024007968A/es unknown
- 2022-12-22 AU AU2022420605A patent/AU2022420605A1/en active Pending
- 2022-12-22 KR KR1020247024194A patent/KR20240117639A/ko active Pending
- 2022-12-22 WO PCT/US2022/082214 patent/WO2023122714A2/en not_active Ceased
- 2022-12-22 CN CN202280091368.6A patent/CN118742567A/zh active Pending
- 2022-12-22 EP EP22912727.9A patent/EP4453036A4/en active Pending
- 2022-12-22 JP JP2024538272A patent/JP2025501028A/ja active Pending
- 2022-12-22 CA CA3240723A patent/CA3240723A1/en active Pending
-
2024
- 2024-06-21 US US18/749,821 patent/US20240352133A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025503339A5 (enExample) | ||
| JP2025503614A5 (enExample) | ||
| US12528876B2 (en) | CD73 blocking antibodies | |
| US12325745B2 (en) | Anti-DLL3 antibodies and uses thereof | |
| EP2768855B1 (en) | Stable multiple antigen-binding antibody | |
| CN119679936A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| CA3118777A1 (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
| WO2021003082A1 (en) | Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof | |
| CN115698074A (zh) | 抗-cd98抗体和其用途 | |
| JP2025514437A5 (enExample) | ||
| EP4095158A1 (en) | Pharmaceutical composition containing anti-btla antibody and use thereof | |
| JP2024510142A5 (enExample) | ||
| WO2018183182A1 (en) | Methods and compositions for reduction of immunogenicity | |
| TW202037365A (zh) | 抗IL17a抗體的水性藥物組合物及其用途 | |
| JP2026001077A5 (enExample) | ||
| JP2024538140A5 (enExample) | ||
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| CN114762678A (zh) | 抗tigit抗体药物组合物及其用途 | |
| CN118382463A (zh) | 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 | |
| CN120603852A (zh) | 一种fap/cd40结合分子的药物组合物及其医药用途 | |
| JP2023502398A5 (enExample) | ||
| JP2024542158A5 (enExample) | ||
| US20240383990A1 (en) | Hinge-modified bispecific antibodies | |
| WO2024153168A2 (en) | Anti-cmet antibodies and methods of use | |
| WO2022184148A1 (zh) | Il-21-抗白蛋白单域抗体融合蛋白药物组合物及其用途 |